Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where There's A Cure There's Controversy: Raymond Schinazi's Story

Executive Summary

It is thought that more than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs Raymond F Schinazi has invented. Most latterly associated with hepatitis C cure sofosbuvir, Schinazi tell Jo Shorthouse why he has no intentions of stopping any time soon.

You may also be interested in...

Industry’s Achievements Lauded At 12th Annual Scrip Awards

The world’s political tectonic plates may be shifting, but this has done little to undermine the achievements of the pharma, biotech and allied industries over the past year, and last night we celebrated the best of these at the 12th annual Scrip Awards in London.

Stockwatch: Game, Pharmasset, and Match?

Just at the moment when markets are more focused on sovereign debt crises and Wall Street is thinking about squatters on its doorstep and looking forward to Thanksgiving, Gilead Sciences steps up and makes an audacious all cash $11 billion bid for Pharmasset. The planned acquisition, which has the full backing of the Pharmasset board, raises more questions than it answers.

Record-Setting Deal For Pharmasset Expected To Boost Value Of Other HCV Biotechs

The $11 billion Gilead plans to pay for Pharmasset dwarfs any prior deal for a clinical-stage biotech, and should be good news for other biotechs with hepatitis C candidates, like Inhibitex, Achillion and Idenix.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts